New Hope for Fatal Childhood Disease as Adrabetadex Nears FDA Decision

THOUSAND OAKS, CA – March 12, 2026 – For families navigating the devastating landscape of infantile-onset Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder, a significant glimmer of hope has emerged. New data presented for an investigational therapy, adrabetadex, shows it can dramatically slow the disease's relentless progression and significantly improve survival rates, a potential landmark achievement for a condition with no approved treatments in the United States.

Beren Therapeutics P.B.C., the company developing the drug, announced the compelling findings at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. The data arrives at a critical time, as the U.S. Food and Drug Administration (FDA) is conducting a Priority Review of the therapy, with a decision expected by August 17, 2026.

The Devastating Reality of Infantile-Onset NPC

Niemann-Pick disease type C is a cruel and unforgiving neurodegenerative disorder. Caused by genetic mutations that prevent the proper transport of cholesterol within cells, it leads to a toxic buildup of fats in the brain, liver, spleen, and other organs. While it can manifest at any age, the infantile-onset form—where neurological symptoms appear before the age of six—is particularly aggressive.

Children with infantile-onset NPC often experience a heartbreaking regression, losing skills they once had. They may face developmental delays, clumsiness, and a characteristic inability to move their eyes up and down, known as vertical supranuclear gaze palsy. As the disease progresses, it robs them of their ability to walk, speak, and swallow, leading to a premature death. For children who develop neurological symptoms before age two, the mean survival is a grim 5.6 years. The profound unmet medical need has left the patient community desperate for a therapy that can do more than just manage symptoms.

A Potential Breakthrough in Clinical Data

The data presented at the ACMG meeting suggests adrabetadex may be the disease-modifying therapy that patients and clinicians have been waiting for. Dr. Elizabeth M. Berry-Kravis, a Professor of Pediatrics at Rush University Medical Center, detailed the findings from studies involving dozens of children with infantile-onset NPC.

In a key analysis of 79 patients, treatment with adrabetadex was associated with a 43% reduction in the annual rate of disease progression over 52 weeks compared to the period before treatment began. This progress was measured using the 4-Domain Composite NPC Clinical Severity Scale (4DNPCCSS), a tool that assesses crucial functions like ambulation, speech, fine-motor skills, and swallowing—the very abilities that NPC systematically destroys.

Even more striking was the survival data. A comparison of 72 adrabetadex-treated children to 119 matched historical controls from natural history studies revealed a 71% reduction in the risk of death. The 5-year survival rate for children on the therapy was 84%, more than double the 42% rate seen in the untreated control group. This represents a profound potential shift in the disease's trajectory.

“There are limited therapies for patients with rapidly progressive and fatal infantile-onset NPC, none of which have demonstrated survival benefit,” said Dr. Berry-Kravis during the presentation. “In view of this data, adrabetadex may potentially slow disease progression and improve survival, offering disease-modifying therapy.”

Unlocking the Science Behind Adrabetadex

Adrabetadex is a proprietary mixture of cyclodextrins, a class of complex sugar molecules. Its mechanism is designed to directly target the root cause of NPC. By facilitating the removal of trapped cholesterol from cells, the therapy aims to re-establish normal intracellular trafficking and, in turn, slow the cascade of neurological damage.

Supporting this theory, the clinical data included significant changes in a key biomarker. Levels of 24(S)-hydroxycholesterol (24(S)-OHC) in the cerebrospinal fluid—an indicator of improved cholesterol processing in the brain—increased by nearly 28% from baseline in treated patients. This provides biological evidence that the drug is having its intended effect within the central nervous system.

While the data suggests the therapy is generally well-tolerated, it is not without side effects. The main adverse events noted in trials include hearing impairment, which can be managed with hearing aids, as well as fatigue and ataxia (loss of coordination) following dosing.

A Mission-Driven Race to Market

The promising clinical results have placed adrabetadex on an accelerated regulatory path. The FDA granted it Breakthrough Therapy Designation in 2025 and accepted it for Priority Review in February 2026, signals that the agency recognizes its potential to address a serious, unmet need. All eyes are now on the PDUFA target action date of August 17, 2026.

For Beren Therapeutics, a founder-led Public Benefit Corporation (P.B.C.), the potential approval of adrabetadex is more than a commercial milestone. Its corporate structure legally obligates it to balance shareholder interests with a public benefit mission—in this case, delivering therapies for devastating diseases. The company has been providing the drug to patients through an Expanded Access Program, underscoring its commitment to the NPC community.

“These biomarker data support Beren’s cholesterol trafficking-based approach, which is grounded in disease biology. If adrabetadex is approved, it would be the first therapeutic option for patients and families designed to target the underlying pathophysiology of NPC with the goal to extend lifespan and slow the progression of this rare and rapidly fatal pediatric neurodegenerative disorder,” said Dr. Alex Gold, Chief Medical Officer of Beren Therapeutics. “We remain focused on working with the FDA to advance our NDA for adrabetadex.”

As the August deadline approaches, a community of patients, families, and physicians holds its breath, hoping that a new era in the fight against Niemann-Pick disease type C is finally within reach.